Abstract
Kynurenine pathway is gaining more and more attention every day in biomedical research since this catabolic route for tryptophan decomposition is not only implicated in different neurological disorders, but also possesses neuroactive metabolites with different biological properties, such as pro-oxidant and antioxidant regulators. Thus, the intensive research on this metabolic pathway is helping us to understand those mechanisms underlying neurodegenerative events during the occurrence of pathological process in the central nervous system (CNS), thereby allowing the design of potential therapies for those disorders involving excitotoxic, oxidative and inflammatory components. Here we intend to provide a brief overview on the relevance of this route for several CNS disorders, and discuss recent information on the different biological properties of the neuroactive metabolites of this pathway and their significance for further research.
Keywords: Kynurenines, thryptophan metabolism, central nervous system, neurotoxicity, disease
CNS & Neurological Disorders - Drug Targets
Title: Kynurenine Pathway and Disease: An Overview
Volume: 6 Issue: 6
Author(s): Abel Santamaria, Veronica Perez-De La Cruz and Mina Konigsberg
Affiliation:
Keywords: Kynurenines, thryptophan metabolism, central nervous system, neurotoxicity, disease
Abstract: Kynurenine pathway is gaining more and more attention every day in biomedical research since this catabolic route for tryptophan decomposition is not only implicated in different neurological disorders, but also possesses neuroactive metabolites with different biological properties, such as pro-oxidant and antioxidant regulators. Thus, the intensive research on this metabolic pathway is helping us to understand those mechanisms underlying neurodegenerative events during the occurrence of pathological process in the central nervous system (CNS), thereby allowing the design of potential therapies for those disorders involving excitotoxic, oxidative and inflammatory components. Here we intend to provide a brief overview on the relevance of this route for several CNS disorders, and discuss recent information on the different biological properties of the neuroactive metabolites of this pathway and their significance for further research.
Export Options
About this article
Cite this article as:
Santamaria Abel, La Cruz Perez-De Veronica and Konigsberg Mina, Kynurenine Pathway and Disease: An Overview, CNS & Neurological Disorders - Drug Targets 2007; 6 (6) . https://dx.doi.org/10.2174/187152707783399229
DOI https://dx.doi.org/10.2174/187152707783399229 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Editorial [Hot Topic: Adenosine-Based Modulation of Brain Activity (Guest Editor: DETLEV BOISON)]
Current Neuropharmacology Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Coenzyme Q10 in Neurodegenerative Diseases
Current Medicinal Chemistry Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Valproic acid, A Potential Inducer of Osteogenesis in Mouse Mesenchymal Stem Cells
Current Molecular Pharmacology GABAA Receptor Specific Pyrazolopyrimidines as Potential Imaging Agents: In Vivo Characteristics of a New 18F-labelled Indiplon Derivative
Current Radiopharmaceuticals Anticonvulsant Activity of New GABA Prodrugs
Medicinal Chemistry Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update
Current Pharmaceutical Design Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design The Relationship Between Epilepsy and Depression: An Update
Current Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry